Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alcon Research
To evaluate the IOP lowering efficacy and safety fo Travoprost 0.004% compared to Timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). The study structure is a parallel design. The patients will receive treatment for 12 weeks.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
≥18 years;
IOP=16-30mmHg
OH or OAG with visual filed abnormality:
1. ≥3 adjacent points in 24 degrees field on the same side of the horizontal meridian, that have p \<5% on the prepapillary diameter plot, one of which must have p \<1%,
2. Glaucoma Hemifield Test outside normal limits,
3. Corrected Pattern Standard Deviation with p \<5%
You may not be if
Previous damage of anterior chamber angle;
ocular inflammation or ocular surgery within the past 3 months; Best Corrected Visual Acuity (logMAR) \<1.0;
contact lens wearer;
severe central field loss;
uncontrolled cardiovascular, hepatic or renal disease;